Adia Nutrition Stock Price, News & Analysis

Adia Nutrition (OTCQB: ADIA) has launched Cherry Payment Plans at its Adia Med clinics, including the flagship location in Winter Park, Florida. The new financing program allows patients to spread treatment costs over monthly installments, making innovative therapies more financially accessible. The initiative was announced by CEO Larry Powalisz and aims to reduce financial barriers to accessing transformative treatments. The Winter Park clinic, which opened in January 2025, is part of Adia Med's expanding clinical network focused on personalized care. Interested patients can learn more about treatment options and financing through the company's website. Additionally, Adia Nutrition is scheduled to present at the Life Sciences Virtual Investor Forum on June 11th, 2025, at 2:00 PM EST.

Adia Nutrition (OTCQB: ADIA) announces expansion of its business model through licensing agreements to meet growing global demand for its regenerative therapies. The company will allow approved clinics worldwide, particularly in the US, Colombia, and Mexico, to operate under the Adia Med brand. Licensed clinics must exclusively source stem cell and exosome products from Adia Labs LLC and maintain Adia Med's quality standards. The program includes access to signature treatments like AdiaVita (100M stem cells, 3T exosomes) and AdiaLink (3.5T exosomes). This strategic move positions Adia Nutrition to capture a larger share of the $15.1B stem cell market while ensuring consistent quality through FDA-registered, cGMP-compliant products.

Adia Nutrition Inc. (OTCQB: ADIA) has successfully uplisted from OTC Pink Sheets to the OTCQB Venture Market in a record-breaking six weeks, compared to the typical 12-16 week timeline. The company also completed SEC Rule 15c2-11 compliance, enhancing transparency and trading liquidity. The uplisting process, completed on May 16, 2025, followed an independent audit with Astra Audit and Advisory LLC on April 1, 2025.

CEO Larry Powalisz highlighted this achievement as part of Adia's strategic vision toward a future Nasdaq Small Cap listing. The company, which specializes in umbilical cord stem cell therapies and premium nutritional products, recently opened its first Florida clinic for regenerative therapies and had its shell risk designation removed.

Adia Nutrition Inc. (OTC Pink: ADIA) has filed for uplisting to the OTCQB Venture Market following a successful independent audit with Astra Audit and Advisory LLC on April 1, 2025. The company is leveraging OTC Markets to handle its Form 15c2-11 filing, which will enable broker-dealers to quote ADIA securities and enhance market maker participation.

The company has also requested the Non-Objecting Beneficial Owners (NOBO) list to improve direct communication with shareholders. These strategic moves aim to increase transparency, liquidity, and market visibility as Adia continues its focus on regenerative medicine, including Umbilical Cord Stem Cell therapies and Autologous Hematopoietic Stem Cell Transplantation. The company's long-term goal includes a potential Nasdaq Small Cap listing.

Adia Nutrition (OTC: ADIA) has announced a significant share structure overhaul, featuring two key developments: the retirement of approximately 15.5 million shares, reducing outstanding common stock from 95.9 million to 80.4 million shares, and the cancellation of a commitment agreement for 10 million additional shares. The retired shares were identified during a review of shares issued without proper documentation. The company is conducting a comprehensive review of share issuance records and plans to file for additional share cancellations if documentation inadequacies are found. CEO Larry Powalisz emphasized the company's commitment to building a transparent capital structure and protecting shareholder interests.

Adia Nutrition Inc. (OTC Pink: ADIA) has filed for uplisting to the OTCQB Venture Market following a successful independent audit with Astra Audit and Advisory on April 1, 2025. The company specializes in regenerative medicine and nutritional wellness, focusing on stem cell therapies and nutritional products.

As part of the uplisting process, OTC Markets will handle Adia's Form 15c2-11, streamlining the broker-dealer quotation process and enhancing transparency. The company has also requested the Non-Objecting Beneficial Owners (NOBO) list to improve direct shareholder communication.

CEO Larry Powalisz emphasized that these strategic moves align with the company's commitment to transparency and growth. The uplisting is part of Adia's broader roadmap toward a potential Nasdaq Small Cap listing, aiming to enhance market credibility and expand its investor base while continuing to develop its clinic network and regenerative medicine solutions.

Adia Nutrition Inc. (OTC Pink: ADIA) has successfully completed an independent audit with Astra Audit and Advisory , a PCAOB-registered auditing firm, positioning the company for uplisting to the OTCQB market. This milestone represents a significant step toward enhanced transparency and investor confidence.

The company, focused on advanced stem cell therapies and nutritional wellness, provides cutting-edge treatments including Umbilical Cord Stem Cell (UCB-SC) treatments and Autologous Hematopoietic Stem Cell Transplantation (aHSCT) nationwide. The planned uplisting to OTCQB is expected to provide greater liquidity and market exposure, supporting the company's expansion of its clinic network and development of innovative therapies for conditions like Multiple Sclerosis.

Adia Nutrition (OTC Pink: ADIA) has announced a significant court ruling ordering the cancellation of over 25 million shares, including more than 15 million restricted common shares and 10 million preferred shares. This decision will reduce the company's outstanding shares by over 15 million.

The company has already contacted the transfer agent to initiate the share cancellation process. According to CEO Larry Powalisz, this reduction in outstanding shares is expected to increase the value of remaining shares by concentrating ownership and improving earnings per share metrics, directly benefiting current investors.

The company anticipates additional strategic initiatives in the near future as it continues to operate in the nutrition and wellness sector.

Adia Nutrition Inc. (OTC Pink: ADIA) has announced the opening of its first satellite location in Tinton Falls, New Jersey, through a strategic shared space agreement with Keep Glowing Medical Spa and Dr. Michael Ellis. The facility will operate under Adia Med, offering FDA-compliant regenerative treatments including AdiaVita and AdiaLink.

The location will provide stem cell therapies targeting inflammation, autoimmune disorders, and musculoskeletal issues. AdiaVita contains 100 million viable cells and 3 trillion exosomes per unit, while AdiaLink offers 3.5 trillion exosomes per unit. These products meet Section 361 of the Public Health Service Act standards.

This expansion follows the launch of Adia's flagship clinic in Winter Park, Florida, in January 2025. The partnership model reduces overhead costs while accessing an established patient base, serving as a template for future nationwide expansion in the $15.1 billion global stem cell market.